Dongwha Pharm.Co.,Ltd (KRX: 000020)

Market Cap	186.26B
Revenue (ttm)	405.75B
Net Income (ttm)	13.90B
Shares Out	27.72M
EPS (ttm)	501.80
PE Ratio	13.39
Forward PE	n/a
Dividend	180.00 (2.71%)
Ex-Dividend Date	Dec 27, 2024

Volume	129,514
Open	6,670.00
Previous Close	6,690.00
Day's Range	6,350.00 - 6,680.00
52-Week Range	6,350.00 - 10,760.00
Beta	1.06
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Dongwha Pharm.Co.,Ltd

Dongwha Pharm.Co.,Ltd manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxants/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, dermatological, mouth and tooth, hepatic protectors, nutrients, tonics, topic analgesic, antihistamines, sore throat, and others; quasi drugs; health su...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1897
• Employees: 793
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 000020

Financial Performance

In 2023, Dongwha Pharm.Co.,Ltd's revenue was 361.11 billion, an increase of 6.08% compared to the previous year's 340.43 billion. Earnings were 27.44 billion, an increase of 34.61%.